ATAI Investment Group Apeiron LTD. buys $22.8M worth of shares
Feb 20, 2025, 5:31 AM
-16.97%
What does ATAI do
ATAI Life Sciences NV, a Berlin-based clinical-stage biopharmaceutical company, focuses on developing treatments for mental health disorders and went public on June 18, 2021. Key compounds include PCN-101 for treatment-resistant depression and DMX-1002 for opioid use disorder.
Investment Group Apeiron LTD. bought 10,835,718 shares of ATAI on 14 February at $2.10 per share, worth a total of $22.8M. They now own 40,555,215 ATAI shares, or a 36% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
